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Summary
BACKGROUND: In recent years, several treatment
modalities have proved to be effective in the treatment of
neuroendocrine tumours (NETs). However, there is cur-
rently no consensus on the sequence in which these op-
tions are best used.
METHODS: In this observational study, we analysed the
treatment modalities and sequences of all patients includ-
ed in the Swiss NeuroEndocrine Tumour registry (Swiss-
NET). SwissNET is a national registry, which has prospec-
tively included patients with a NET from all regions of
Switzerland since 2008.
RESULTS: The registry includes 1366 patients; 1063 had
documented therapies after the main diagnosis and were
included in the analysis. The median follow-up time was
1.86 years. The most common primary site was the small
intestine (291 patients, 27%) followed by pancreas (254
patients, 24%), lung (172 patients, 16%) and appendix
(163 patients, 15%). A total of 167 different therapy se-
quences were observed. In 708 (67%) patients, surgery
was the only treatment. The sequence of surgery followed
by chemotherapy was most frequently documented in
poorly (G3) differentiated (24 patients, 60%) and pancreat-
ic (15 patients, 34%) NETs. Tumours treated with surgery
followed by biotherapy or followed by peptide receptor ra-
dionuclide therapy (PRRT) were predominantly well-dif-
ferentiated G1 NETs of the small intestine. In patients
who were treated with either PRRT or systemic therapy
(chemotherapy or molecular therapy) or both, PRRT was
used more frequently than systemic therapy in patients
with a small intestinal NET (35 patients, 62% vs 30, 54%),
whereas the opposite held true in pancreatic (44 patients,
59% vs 56, 70%) and lung NETs (6 patients, 14% vs 40,
97%). If both chemotherapy and molecular therapy were
used, chemotherapy was applied prior to molecular thera-
py in 13 of 19 (68%) patients with a pancreatic NET.
CONCLUSION: Surgery represents the treatment of
choice in most patients with a NET irrespective of tumour
stage. In patients receiving additional treatment, an im-
pressive variety of treatment sequences were document-
ed. In small intestinal NETs, patients received PRRT more
often than chemotherapy, whereas the opposite holds true
for patients with pancreatic and lung NETs.
Keywords: NET, neuroendocrine tumour, treatment, se-
quence, chemotherapy, PRRT
Introduction
Neuroendocrine tumours (NETs) represent a rare and high-
ly heterogeneous tumour entity with increasing incidence
[1]. Based on population-based registry data, approximate-
ly 50% of NETs arise from the gastrointestinal tract, one
quarter from the lungs and, in third place, 6% from the pan-
creas [2]. The incidence rate of pancreatic NETs has signif-
icantly increased during the last decade, whereas the inci-
dence rate of lung NETs is reported to be rather stable [3].
Goals of antiproliferative treatment options for patients
with locally advanced and metastatic NETs include the re-
duction of tumour burden, delay of tumour progression,
prolongation of life and improvement in quality of life.
Current treatment modalities regularly used to achieve
these aims consist mainly of surgery, antiproliferative
drugs and peptide receptor radionuclide therapy (PRRT).
Systemic drug therapy includes somatostatin analogues,
cytotoxic drugs (chemotherapy) and targeted treatment op-
tions (molecular therapy). Because of the rarity of NET,
large randomised, placebo-controlled trials assessing the
efficacy of these treatments in the locally advanced,
metastatic setting are limited. In the PROMID trial oc-
treotide LAR significantly increased progression-free sur-
vival compared with placebo in patients with a metastatic
midgut NET, irrespective of functionality [4]. Correspond-
ingly, lanreotide significantly prolonged progression-free
survival among patients with a well-differentiated (Ki-67
<10%) metastatic enteropancreatic NET in the ran-
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domised, double-blind, placebo-controlled, multinational
Clarinet trial [5]. Chemotherapy regimens (streptozocin,
5-fluorouracil, doxorubicin, capecitabine, temozolomide,
oxaliplatin) were investigated in retrospective and small
prospective phase II trials [6–8]. Sunitinib, an oral, small-
molecule, multi-targeted receptor tyrosine kinase inhibitor
and everolimus, an inhibitor of mammalian target of ra-
pamycin (mTOR) significantly improve progression-free
survival in well-differentiated NETs [9, 10]. In the NET-
TER-1 trial treatment with 177Lu-Dotatate resulted in
markedly longer progression-free survival and a signifi-
cantly higher response rate than high-dose octreotide LAR
among patients with an advanced midgut NET [11].
Currently, clinical trials addressing the issue of optimal
treatment sequencing are limited. For example, the effica-
cy and safety of PRRT with 177Lu-Edotreotide compared
with targeted molecular therapy with everolimus is being
studied in a prospective, randomised phase III trial in pa-
tients with inoperable NETs of gastroenteric or pancreatic
origin (NCT03049189). Outside clinical trials, patient and
tumour characteristics as well as treatment goals (disease
stabilisation, tumour shrinkage) are taken into considera-
tion to decide on the best treatment strategy. Additionally,
physician expertise and regulatory issues with regard to
access to novel treatments affect the choice of treatment.
Based on those parameters, the ENETS (European Neu-
roendocrine Tumor Society) published guidelines to facili-
tate treatment decision [12]. In view of the lack of evidence
regarding the optimal treatment sequence to improve pa-
tient outcome, assessing the presence of a potential treat-
ment consent in daily clinics is valuable.
Primarily, this research project aims to illuminate the NET
treatment sequence used in the clinical setting outside of
clinical trials based on a large, national, prospectively con-
ducted registry (SwissNET). Secondly, we assessed the se-
quence of systemic drug therapy (chemo- and molecular
therapy) and PRRT on the one hand and the sequence of
chemo- and molecular therapy in respect to the different
primary NET sites.
Material and methods
Study design and population
The SwissNET registry is a nationwide prospective data-
base documenting data on patients with NET in Switzer-
land since 2008. Ethical approval to run the registry was
obtained from the lead ethics committee in Bern (Kan-
tonale Ethikkomission Bern; No: 395/2014). Currently, 56
participating hospitals and private practices are providing
SwissNET with their patient information. Accrual sites in
the SwissNET registry are presented in supplementary fig-
ure S1 (appendix 1). All documented patients have signed
a written informed consent form, agreed to their medical
records being collected within SwissNET and agreed that
the pseudonymised data can be used for research purposes.
Patients with a NET of the aerodigestive tract with the
exclusion of small/large cell neuroendocrine carcinoma of
the lung are registered in SwissNET. The current classi-
fication is based on the revised World Health Organiza-
tion (WHO) criteria 2010 for NETs of gastroenteropancre-
atic origin and the 2004 WHO classification for lung NETs
[13]. Medical records are regularly screened and clinical
information, including NET treatment modalities are doc-
umented by trained study nurses.
The main outcome was defined by the description of the
patients’ demographics (age), tumour characteristics (pri-
mary site, tumour grade, functionality), all documented
treatment modalities and sequence in the main analysis
set representing the entire SwissNET cohort (cut-off date
25 July 2017). Treatment modalities were divided into
surgery, biotherapy (somatostatin analogues), chemother-
apy, molecular therapy (sunitinib, everolimus), PRRT and
local ablative therapy (percutaneous radiotherapy, ra-
diofrequency ablation, etc.). Treatment sequencing was
based on the date of therapy start. Repeated therapies of the
same type were pooled if the time between the consecutive
therapy starts was less than 6 months.
Biotherapy, in particular the short-acting formulation, is
often used concomitantly to other systemic therapies in
functional NETs precluding sequence analysis with this re-
gards [14]. The limited documentation in the medical his-
tory of exact treatment details regarding biotherapy (main-
ly treatment dose, interval and end) hampered proper
analysis of biotherapy in this context. Therefore, the use of
biotherapy was analysed separately.
Based on a secondary analysis set, we assessed sequences
used for small intestinal, pancreatic and lung NETs and
studied the order of use of systemic therapy (chemotherapy
and/or molecular therapy) and PRRT and the sequence of
molecular therapy (sunitinib, everolimus) and chemothera-
py. Local ablative and biotherapy as such were excluded in
the secondary analysis set. Both treatment modalities are
often used concomitantly with chemo-, molecular therapy
and PRRT hampering sequence analysis.
Statistical analysis
Patient and disease characteristics were analysed using de-
scriptive statistics. We reported the number of non-missing
observations for patient and tumour characteristics. For the
treatment sequences, we were limited to documented treat-
ments. However, we expect that the documentation of the
treatments is complete as trained study nurses regularly up-
date all entries.
Continuous and categorical variables are presented as me-
dian and interquartile range (IQR) or number and percent-
age of patients. All analyses were done in Stata Release 14
(Ref: StataCorp. 2015. Stata Statistical Software: Release
14. College Station, TX: StataCorp LP.).
Results
Patient and tumour characteristics in the SwissNET
cohort
The Swiss Neuroendocrine Tumor registry comprises 1366
patients, with documented therapies in 1063 cases. The
median follow-up time was 1.86 years (interquartile range
[IQR] 0.35–4.03). The most common primary site was the
small intestine (291 tumours; 27%) followed by pancreas
(254 tumours, 24%), lung (172 tumours; 16%) and appen-
dix (163 tumours; 15%). A majority of the NET were well-
differentiated G1 and G2 (78%). The detailed patient and
tumour characteristics are presented in table 1.
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Treatment sequences in the SwissNET cohort
The different treatment modalities given to the patients
in the entire SwissNET cohorts are documented in table
2. Most of the patients underwent surgery (935 patients;
88%) in the course of their disease. Only a minority of
patients were received non-surgical treatment modalities.
Overall, 158 (15%), 156 (15%) and 113 (11%) patients re-
ceived biotherapy, chemotherapy or PRRT, respectively.
A total of 167 different therapy sequences were observed
(table 3). Out of these, 40 (24%) were used in more than
one patient. In 708 (67%) patients, surgery was the only
treatment appendical NETs, representing the most com-
mon primary tumour site treated with surgery only. Twenty
patients (2%) and 12 patients (1%) were treated only with
chemotherapy and biotherapy, respectively.
Overall, 311 patients (29%) received more than one treat-
ment modality. For the first two treatment modalities the
most common sequences were surgery followed by bio-
therapy in 45 (14%), surgery followed by chemotherapy in
44 (14%) and surgery followed by PRRT in 36 (12%) pa-
tients (table 4).
Treatment sequence according to primary tumour lo-
cation in the secondary analysis set
Small intestinal neuroendocrine tumours
The treatment sequences of 288 small intestinal NET pa-
tients were analysed (figure 1). Surgery was the only treat-
ment in 214 patients (74%). Systemic drug therapy only
and PRRT only were given to 5 (2%) and 1 (0%) patients,
respectively. After surgery, PRRT was applied most fre-
quently (29 patients; 10%). Surgery followed by another
tumour resection was noted in 21 (7%) and surgery fol-
lowed by systemic drug therapy in 15 patients (5%).
The use of systemic drug therapy and PRRT and the use
of chemo- or molecular therapy and the corresponding se-
quence of these two treatment modalities are shown in
table 5. Fifty-six patients (19%) with small intestinal NETs
Table 1: Patient and tumour characteristics (n = 1063 patients).
n (%) or median (IQR)
Age at diagnosis (years) 61 (50–71)
Sex Female 504 (47%)
Male 559 (53%)
Primary site Small intestine 291 (27%)
Pancreas 254 (24%)
Lung 172 (16%)
Appendix 163 (15%)
Unknown 64 (6%)
Colorectal 50 (5%)
Stomach 38 (4%)
Oesophagus 3 (0%)
Other 26 (2%)
Not documented 2 (0%)
Diagnosis Neuroendocrine tumour 759 (71%)
Neuroendocrine carcinoma 304 (29%)
Functioning No 732 (69%)
Yes 141 (13%)
Not documented 190 (18%)
Tumour grade at baseline G1 598 (56%)
G2 229 (22%)
G3 92 (9%)
Not documented 144 (13%)
Tumour stage at baseline I 184 (17%)
II 81 (8%)
III 117 (11%)
IV 75 (7%)
Not documented 606 (57%)
Follow-up time after major diagnosis (y) 1.86 (0.35–4.03)
IQR = interquartile range
Table 2: Therapies in the main analysis set (n = 1063).
n (%)
Surgery 935 (88%)
Biotherapy 158 (15%)
Chemotherapy 156 (15%)
PRRT 113 (11%)
Ablative therapy 111 (10%)
Molecular therapy 53 (5%)
PRRT = peptide receptor radionuclide therapy
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were treated with either PRRT or systemic therapy
(chemotherapy and/or molecular therapy) or both. In this
cohort PRRT was used slightly more frequently than sys-
temic therapy (35 patients [62%] vs 30 patients [54%]).
When both modalities were used, PRRT was more fre-
quently applied before systemic therapy than vice versa (8
patients [14%] vs 1 patient [2%]). Thirty patients (10%)
with a small intestinal NET were treated with either mol-
ecular therapy or chemotherapy or both. Again, in this co-
hort, chemotherapy was used more frequently (22 patients
[73%] vs 11 patients [37%]).
Pancreatic neuroendocrine tumours
In total, 251 pancreatic NET patients were analysed for
their treatment sequence. Surgery was the only treatment
for 169 patients (67%). Systemic drug therapy only and
PRRT only were given to 4 (2%) and 3 (1%) patients,
respectively. After surgery, systemic therapy was applied
most frequently, in 17 patients (7%). The detailed treat-
ment sequences are depicted in figure 2.
The use of systemic drug therapy and PRRT, and the use
of chemo- or molecular therapy and the corresponding se-
quence of these two treatment modalities are shown in
table 5. Seventy-five patients (30%) with a pancreatic NET
were treated with either PRRT or systemic therapy or both.
In this patient group, systemic therapy was used more
frequently than PRRT (56 patients [75%] vs 44 patients
[59%]). When both modalities were used, chemotherapy
was more frequently applied before PRRT than vice versa
(14 patients [19%] vs 11 patients [15%]). Fifty-six patients
(22%) with a pancreatic NET were treated with either
molecular therapy or chemotherapy or both. Thereby,
chemotherapy was used more frequently than molecular
therapy (50 patients [89%] vs 25 patients [45%]) and more
frequently before than after (13 patients [23%] vs 6 pa-
tients [11%]).
Lung neuroendocrine tumours
In total, 170 lung NET patients were analysed for their
therapy sequence. Surgery was the only treatment for 127
patients (75%). Systemic drug therapy only and PRRT only
were given to 17 (10%) and 1 (1%) patients, respectively.
Further treatment sequences are illustrated in figure 3.
The sequence whether systemic drug therapy or PRRT and
whether chemo- or molecular therapy was given first are
demonstrated in table 5. 41 patients (24%) with lung NET
were treated with either PRRT or systemic therapy or both.
Table 3: All therapy sequences in the main analysis set (n = 1063).
Sequence n (%)
S 708 (66.1%)
SB 25 (2.4%)
SC 22 (2.1%)
C 20 (1.9%)
SS 18 (1.7%)
SP 14 (1.3%)
B 12 (1.1%)
SA 9 (0.8%)
BS 8 (0.8%)
A, CA, P, SCC 6 (0.6%) × 4 = 24 (2.3%)
CC, PB, SSA 5 (0.5%) × 3 = 15 (1.4%)
SBB, SPB 4 (0.4%) × 2 = 8 (0.8%)
AS, CACA, CM, PC, SAC, SBS, SCA, SCAC, SPBB 3 (0.3%) × 9 = 27 (2.5%)
AC, BCCBC, BM, BPB, CAA, CAAC, CAC, PBP, PP, SAB, SAS, SPC, SSAS 2 (0.2%) × 13 = 26 (2.4%)
ABC, ACAC, ACPMA, ASA, ASB, ASBB, ASCA, BB, BCP, BMBPB, BMBPPMS, BMCMC, BPBBCBC, BPBC, BPBP, BPM, BPSA,
BSASSSMC, BSB, BSBP, BSBPB, BSBSBPSPB, BSC, BSCM, BSP, BSPM, CAACA, CAACAC, CAACS, CAB, CABCPBM, CA-
CACA, CACCC, CACSA, CAM, CASA, CBACA, CBCMBPBAPSCA, CBM, CBMC, CCCPP, CCS, CMAB, CMAMMAC, CMCAB,
CMCCB, CPA, CPC, CPMAC, CPPMB, CS, CSABMP, CSAPBB, CSC, CSM, CSPP, MB, MBC, MBM, MSC, PBBBP, PBBM,
PBBP, PBCBPC, PBM, PBPSPP, PCSCC, PMBPAC, PPB, PPP, PS, PSP, SAAPSBCMB, SABSBAMMCBC, SABSPPP, SACS,
SAM, SAPAMSABM, SAPB, SAPBB, SASB, SASPMAM, SASSCCCP, SBABS, SBAS, SBBAP, SBC, SBM, SBMMMS, SBP,
SBPBB, SBPBMA, SBPPBBMBSB, SBPPBCPBM, SBPS, SBSA, SCASPC, SCBCB, SCBCBCM, SCCB, SCCC, SCM, SCMBBA,
SCPB, SCPBA, SCPBS, SMASCM, SPABC, SPBABB, SPBAS, SPBP, SPBPBPBPM, SPCB, SPCP, SPM, SPMCACCACPB,
SPPP, SPS, SPSASPMBMB, SPSBB, SSAB, SSBMMB, SSBPBPBBS, SSP, SSPP, SSSAM, SSSS
1 (0.1%) × 127 = 127 (11.9%)
A = ablative therapy; B = biotherapy; C = chemotherapy; M = molecular therapy; P = PRRT = peptide receptor radionuclide therapy; S = surgery
Table 4: Patient characteristics for groups defined by the first two therapies in the main analysis set.
Group Patients
(n = 311)
n (%)
Age at diagnosis in years
Median (IQR)
Main primary site
n (%)
Tumour grade
n (%)
Functioning
n (%)
SB 45 (14%) 66.0 (48.0–48.0) Small intestine (33, 73%) G1 (22, 54%) 13 (29%)
SC 44 (14%) 62.0 (54.8–54.8) Pancreas (15, 34%) G3 (24, 60%) 2 (5%)
SP 36 (12%) 60.5 (50.0–50.0) Small intestine (18, 50%) G1 (17, 53%) 8 (22%)
SS 32 (10%) 58.0 (51.0–51.0) Small intestine (18, 56%) G1 (19, 70%) 3 (9%)
SA 27 (9%) 61.0 (45.0–45.0) Pancreas (12, 44%) G2 (12, 52%) 3 (11%)
CA 25 (8%) 66.0 (59.0–59.0) Lung (17, 68%) G3 (11, 85%) 1 (4%)
BS 17 (5%) 65.0 (50.0–50.0) Small intestine (8, 47%) G1 (8, 62%) 8 (47%)
PB 13 (4%) 65.0 (54.0–54.0) Unknown (5, 38%) G1 (5, 63%) 3 (23%)
A = ablative therapy; B = biotherapy; C = chemotherapy; M = molecular therapy; P = PRRT; S = surgery Only combinations with >10 patients are shown
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In this cohort systemic therapy was used more frequently
than PRRT, in 40 patients (97%) vs 6 patients (14%), re-
spectively. In the cohort treated with either molecular ther-
apy or chemotherapy or both chemotherapy was used more
frequently than molecular therapy (39 patients [98%] vs 5
patients [13%]).
Biotherapy (somatostatin analogues)
Treatment with somatostatin analogues was documented in
158 patients (15%). In 53 patients of these patients (34%)
no surgical therapy was performed in the disease course.
Surgery followed by biotherapy and biotherapy followed
by surgery could be documented in 70 (44%) and 17 pa-
tients (11%), respectively. For functional NETs, biotherapy
was given more often before surgery. There was no other
obvious difference in patient and tumour characteristics ac-
cording to the biotherapy sequence groups (supplementary
table S1, appendix 1).
Discussion
The main findings of this study can be summarised as fol-
lows:
1. Surgery is the treatment of choice in most NETs irre-
spective of tumour stage.
2. Only a small proportion of NET patients receive other
treatment modalities in their disease course.
3. If patients treated with surgery only are excluded,
there is a seemingly unlimited variety of treatment
sequences used in NET patients.
Figure 1: Tree plot for small intestinal neuroendocrine tumours based on the secondary analysis set.Each row represents a therapy line. Stop
indicates that no more treatments were documented. (n = 288 patients). PPRT = peptide receptor radionuclide therapy
Table 5: Therapy sequence groups: peptide receptor radionuclide therapy (PRRT) versus systemic therapy (molecular or chemotherapy) and molecular versus chemotherapy.
Small intestine Pancreas Lung
n (%)
PRRT vs systemic therapy n = 56 n = 75 n = 41
PRRT but no systemic therapy 26 (46%) 19 (25%) 1 (2%)
Systemic therapy but no PRRT 21 (38%) 31 (41%) 35 (85%)
PRRT prior to systemic therapy 8 (14%) 11 (15%) 2 (5%)
Systemic therapy prior to PRRT 1 (2%) 14 (19%) 3 (7%)
Molecular vs chemotherapy n = 30 n = 56 n = 40
Molecular but no chemotherapy 8 (27%) 6 (11%) 1 (3%)
Chemo- but no molecular therapy 19 (63%) 31 (55%) 35 (88%)
Molecular prior to chemotherapy 1 (3%) 6 (11%) 1 (3%)
Chemo- prior to molecular therapy 2 (7%) 13 (23%) 3 (8%)
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4. PRRT seems to be preferred over systemic
therapy in patients with small intestinal NETs,
whereas the opposite is true in pancreatic and
lung NETs.
5. Chemotherapy seems to be preferred over
molecular therapy regardless of tumour site.
Our analysis confirms that tumour resection plays a major
role for the treatment of NETs. The broad indication for
surgical treatment explains this observation. Surgery is
considered to be the treatment of choice for patients who
have a localised well-differentiated NET, for predominant-
ly hepatic disease in the metastatic setting with potentially
curative intent and, importantly, to reduce tumour burden
and thus symptoms of carcinoid syndrome [15].
In the case of multifocal tumour progression, evidence is
limited with regard to which treatment option should be
preferred in which situation. Therefore, studying the se-
quence of treatment modalities (e.g., PRRT, chemothera-
py) and to a lesser extent local therapies is highly relevant
to preventing disease progression and improving outcome
[14, 16, 17]. Recently, treatment patterns in advanced
NETs of the pancreas and potential differences between the
treatment in an academic hospital and community oncolo-
gy practices were reported. Patients treated within the aca-
demic tertiary cancer centre received more lines of ther-
apy, were more likely to undergo surgery (47.8 vs 6.5%)
including liver-directed therapy and were less often treated
with somatostatin analogues (23.8 vs 45.8%). However,
the number of patients assessed (n = 44) was small [18].
The diversity of nonsurgical treatment sequences in our
study is impressive and might reflect firstly the complexity
of the disease and secondly the lack of guidance from clin-
ical studies. Nevertheless, we were able to find some com-
monalities in the use of different treatment approaches.
Note, sunitinib and everolimus gained approval by the Eu-
ropean Medical Agency for the treatment of pancreatic
NETs in 2010 and 2011, respectively. In 2016, everolimus
received approval for treatment of non-pancreatic types of
NET, too. PRRT was available in Switzerland during the
whole registry period.
Small intestinal neuroendocrine tumours
Tumours treated with surgery followed by biotherapy or
followed by PRRT were mostly well-differentiated (G1)
NETs of the small intestine. These findings are completely
in line with the recently published tumour site-specific
guidelines of the European Neuroendocrine Tumor Society
(ENETS) [12, 19, 20]. Chemotherapy is not recommended
in non-pancreatic NETs unless for tumours with a high
proliferation index indicating aggressive biological behav-
iour or those with somatostatin receptor negativity. So-
matostatin analogues may be used in stable or progressive
disease for antiproliferative purposes and are mainly rec-
ommended as a first-line therapy in midgut NETs.
Assessment of the treatment sequence for PRRT and sys-
temic therapy showed that most patients received PRRT
Figure 2: Tree plot for pancreatic neuroendocrine tumours based on the secondary analysis set.Each row represents a therapy line. Stop indi-
cates that no more treatments were documented. (n = 251 patients). PPRT = peptide receptor radionuclide therapy
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first. There are mainly two reasons for this observation.
Firstly, most studies in midgut NETs report on an only
modest response rate of streptozocin- and temozolomide-
containing chemotherapy in this specific NET subtype [21,
22]. Additionally, the evidence for the use of molecular
therapies such as sunitinib or everolimus in small intestinal
NETs, was limited until recently when the results of the
RADIANT-4 trial were published [10]. Further evidence
for the use of PRRT was provided by the phase III ran-
domised controlled NETTER-1 trial, which assessed the
efficacy and safety of 177Lu-DOTATATE in patients with
advanced, somatostatin receptor-positive, G1/G2 midgut
NETs that were progressing on long-acting octreotide. Ob-
jective tumour responses were reported in 18% of patients
who received PRRT compared with 3% in those who did
not. At the time of primary endpoint analysis, the median
progression-free survival had not been reached for the pa-
tients who received PRRT and was 8.4 months in the con-
trol group [11]. Owing to the limited patient numbers no
conclusion can be drawn regarding the sequence of chemo-
and molecular therapy.
Pancreatic neuroendocrine tumours
Based on the current evidence there are rather more ac-
cepted treatment options for patients with pancreatic NETs
compared with NETs of other primary sites [12]. The se-
quence of surgery followed by chemotherapy was most
frequently documented in poorly differentiated (G3) and
pancreatic NETs. These findings correlate with the current
literature. Streptocotozin- and temozolomide-containing
chemotherapy combinations are associated with a high tu-
mour response rate (up to 70%) in NETs of pancreatic ori-
gin [6, 7]. In contrast, the chemo-responsiveness of gas-
trointestinal NETs seems to be very limited [23].
Additionally, Sorbye et al. reported a significant benefit
of platinum-based chemotherapy in poorly differentiated
NETs with a proliferation fraction of >55% [24].
Nevertheless, in patients receiving both PRRT and sys-
temic therapies, no clear pattern in treatment sequences
could be observed in our analysis. Given the different es-
tablished and approved therapeutic options in pancreatic
NETs and the lack of a prospective trial with PRRT in
pancreatic NETs, PRRT is generally recommended in G1/
G2 NETs after failure of medical therapy including a so-
matostatin analogue, chemotherapy or novel targeted drugs
[12]. There are several prospective and retrospective stud-
ies looking at tumour response to PRRT and survival out-
comes for patients with a pancreatic NET, [25, 26]. Ra-
mage et al. reported a median disease control rate and
objective response rate of 83% (range 50–94%) and 58%
(range 13–73%), respectively [27]. Notably, chemotherapy
in pancreatic NETs was more commonly used first fol-
lowed by molecular therapy than vice versa. This might be
explained by the higher response rate with chemotherapy
in pancreatic NETs when compared with molecular thera-
pies, sunitinib and everolimus rather leading to disease sta-
bilisation [9, 10].
Lung neuroendocrine tumours
When compared with PRRT, systemic drug treatment
modalities, and in particular chemotherapy, were more
commonly used in lung NET patients. This is surprising as
the evidence for the use of chemotherapy for pulmonary
NETs is very low. Platinum-based chemotherapy and
temozolomide were studied in rather small retrospective
Figure 3: Tree plot for lung neuroendocrine tumours based on the secondary analysis set.Each row represents a therapy line. Stop indicates
that no more treatments were documented. (n = 170 patients). PPRT = peptide receptor radionuclide therapy
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cohorts with a reported response rate in thoracic NETs
of 0–67% and progression-free survival in the range of
10 months [28, 29]. Only a few phase II trials assessed
the potential efficacy of cytotoxic drugs. Oxaliplatin-based
chemotherapy was associated with a response rate of 14%
[30]. Notably, Imhof et al. investigated in a phase II trial
the efficacy of PRRT in NETs and reported a response rate
of 29% in the lung NET subgroup [31]. The rarity of lung
NETs has precluded further prospective trials in the past.
Again, the small cohorts in our study hampered a meaning-
ful sequence analysis of nonsurgical therapies and there-
fore further interpretation.
Strengths and limitations
The strength of our study is based on the large cohort, the
high quality and completeness of data assessment within
the SwissNET database. The prospective nature of the reg-
istry and data collection by highly dedicated, specialised
study nurses ensures high data quality. Despite the rarity
and heterogeneity of this disease, data on the treatment of
NETs of the main primary sites are provided in this analy-
sis. There are several limitations of our analysis. The na-
ture of the data is observational and the follow-up time
relatively short. Although the total number of intestinal,
pancreatic and lung NET patients analysed is high, the
small sample size in several treatment cohorts hampers
drawing consequences.
Future prospects
Ongoing and future research should improve knowledge
around the molecular biology of NET and efficacy of dif-
ferent sequencing or combination strategies. An ongoing
Phase III clinical trial, the SEQTOR trial, studies the right
treatment sequence for patients with NET of pancreatic
origin assessing the best treatment strategy comparing the
efficacy of everolimus followed by streptozotocin/fluo-
rouracil or vice versa (NCT02246127). Additionally, the
results of the COMPETE trial assessing prospectively the
optimal first-line therapy (PRRT with 177Lu-Edotreotide
compared to everolimus) in patients with an inoperable
NET of gastroenteric or pancreatic origin are eagerly
awaited (NCT03049189). A randomised phase III trial of
lanreotide autogel versus placebo in advanced, unre-
sectable lung NETS is ongoing (NCT02683941).
Conclusion
We present the largest cohort reporting on the treatment
sequence in patients suffering from NETs of any primary
site. Our report illustrates the omnium gatherum of used
treatment modalities and sequences. Surgery is clearly the
treatment option of choice when feasible. If additional
therapies are required, PRRT seems to be preferred to sys-
temic therapy in patients with small intestinal NETs,
whereas systemic therapy is favourably used in pancreatic
and lung NETs.
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Appendix 1 Supplementary data
Figure S1: Accrual sites in the SwissNET registry.
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Table S1: Patient characteristics according to biotherapy sequence groups.
Total
(n = 158)
Biotherapy prior to
surgery
(n = 17)
Surgery prior to bio-
therapy
(n = 70)
Both
(n = 18)
No surgery
(n = 53)
n (%) or median (IQR)
Age at diagnosis (years) 62.0 (49.0–71.0) 65.0 (50.0–69.0) 58.5 (47.0–70.0) 58.0 (48.0–72.0) 65.0 (57.0–71.0)
Sex Female 65 (41%) 7 (41%) 28 (40%) 7 (39%) 23 (43%)
Male 93 (59%) 10 (59%) 42 (60%) 11 (61%) 30 (57%)
Primary site Lung 6 (4%) 0 (0%) 3 (4%) 0 (0%) 3 (6%)
Pancreas 52 (33%) 6 (35%) 24 (34%) 3 (17%) 19 (36%)
Small intestine 59 (37%) 6 (35%) 35 (50%) 11 (61%) 7 (13%)
Colorectal 4 (3%) 1 (6%) 3 (4%) 0 (0%) 0 (0%)
CUP 33 (21%) 4 (24%) 3 (4%) 4 (22%) 22 (42%)
Other 3 (2%) 0 (0%) 2 (3%) 0 (0%) 1 (2%)
Not known 1 (1%) 0 (0%) 0 (0%) 0 (0%) 1 (2%)
Diagnosis Neuroendocrine tumour 91 (58%) 12 (71%) 41 (59%) 13 (72%) 25 (47%)
Neuroendocrine carcinoma 67 (42%) 5 (29%) 29 (41%) 5 (28%) 28 (53%)
Functioning No 77 (49%) 5 (29%) 45 (64%) 5 (28%) 22 (42%)
Yes 51 (32%) 8 (47%) 13 (19%) 9 (50%) 21 (40%)
Not known 30 (19%) 4 (24%) 12 (17%) 4 (22%) 10 (19%)
Tumor grade at baseline G1 58 (37%) 5 (29%) 30 (43%) 7 (39%) 16 (30%)
G2 61 (39%) 6 (35%) 29 (41%) 9 (50%) 17 (32%)
G3 7 (4%) 0 (0%) 4 (6%) 0 (0%) 3 (6%)
Tumor stage at baseline I 3 (2%) 1 (6%) 2 (3%) 0 (0%) 0 (0%)
II 5 (3%) 0 (0%) 5 (7%) 0 (0%) 0 (0%)
III 15 (9%) 2 (12%) 9 (13%) 2 (11%) 2 (4%)
IV 33 (21%) 4 (24%) 19 (27%) 8 (44%) 2 (4%)
Follow-up time after major diagnosis (years) 2.87 (1.40–4.39) 3.39 (0.87–4.52) 3.41 (1.61–5.45) 3.38 (1.40–4.88) 2.30 (1.39–3.48)
CUP = cancer of unknown primary origin; IQR = interquartile range
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